- Home
- CTNM vs FDMT Comparison
CTNM vs FDMT Comparison
Compare CTNM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- FDMT
- Stock Information
- Founded
- CTNM 2009
- FDMT 2013
- Country
- CTNM United States
- FDMT United States
- Employees
- CTNM N/A
- FDMT N/A
- Industry
- CTNM
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- CTNM
- FDMT Health Care
- Exchange
- CTNM Nasdaq
- FDMT Nasdaq
- Market Cap
- CTNM 378.7M
- FDMT 420.7M
- IPO Year
- CTNM 2024
- FDMT 2020
- Fundamental
- Price
- CTNM $14.14
- FDMT $6.15
- Analyst Decision
- CTNM Strong Buy
- FDMT Buy
- Analyst Count
- CTNM 4
- FDMT 10
- Target Price
- CTNM $29.25
- FDMT $42.44
- AVG Volume (30 Days)
- CTNM 82.5K
- FDMT 724.9K
- Earning Date
- CTNM 11-06-2024
- FDMT 11-13-2024
- Dividend Yield
- CTNM N/A
- FDMT N/A
- EPS Growth
- CTNM N/A
- FDMT N/A
- EPS
- CTNM N/A
- FDMT N/A
- Revenue
- CTNM N/A
- FDMT $17,000.00
- Revenue This Year
- CTNM N/A
- FDMT N/A
- Revenue Next Year
- CTNM N/A
- FDMT $87.55
- P/E Ratio
- CTNM N/A
- FDMT N/A
- Revenue Growth
- CTNM N/A
- FDMT N/A
- 52 Week Low
- CTNM $12.33
- FDMT $6.32
- 52 Week High
- CTNM $22.00
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- FDMT 28.94
- Support Level
- CTNM N/A
- FDMT $6.42
- Resistance Level
- CTNM N/A
- FDMT $7.58
- Average True Range (ATR)
- CTNM 0.00
- FDMT 0.42
- MACD
- CTNM 0.00
- FDMT -0.06
- Stochastic Oscillator
- CTNM 0.00
- FDMT 1.85
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.